Oxford Nanopore Technologies Past Earnings Performance
Past criteria checks 0/6
Oxford Nanopore Technologies's earnings have been declining at an average annual rate of -16.9%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 6.8% per year.
Key information
-16.9%
Earnings growth rate
-12.3%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 6.8% |
| Return on equity | -27.5% |
| Net Margin | -94.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Oxford Nanopore Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 168 | -159 | 154 | 102 |
| 31 Mar 24 | 169 | -157 | 154 | 103 |
| 31 Dec 23 | 170 | -155 | 155 | 103 |
| 30 Sep 23 | 166 | -143 | 156 | 95 |
| 30 Jun 23 | 162 | -131 | 157 | 88 |
| 31 Mar 23 | 180 | -111 | 149 | 74 |
| 31 Dec 22 | 199 | -91 | 141 | 59 |
| 30 Sep 22 | 198 | -122 | 160 | 62 |
| 30 Jun 22 | 197 | -153 | 179 | 65 |
| 31 Mar 22 | 165 | -160 | 170 | 70 |
| 31 Dec 21 | 134 | -168 | 162 | 76 |
| 30 Sep 21 | 129 | -119 | 121 | 66 |
| 30 Jun 21 | 125 | -71 | 80 | 55 |
| 31 Mar 21 | 119 | -66 | 76 | 52 |
| 31 Dec 20 | 114 | -61 | 71 | 49 |
| 31 Dec 19 | 52 | -72 | 66 | 40 |
| 31 Dec 18 | 33 | -53 | 42 | 37 |
| 31 Dec 17 | 14 | -57 | 38 | 35 |
| 31 Dec 16 | 5 | -59 | 26 | 38 |
| 31 Dec 15 | 1 | -39 | 17 | 27 |
| 31 Dec 14 | 0 | -37 | 13 | 28 |
Quality Earnings: 4R0 is currently unprofitable.
Growing Profit Margin: 4R0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4R0 is unprofitable, and losses have increased over the past 5 years at a rate of 16.9% per year.
Accelerating Growth: Unable to compare 4R0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4R0 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (5.4%).
Return on Equity
High ROE: 4R0 has a negative Return on Equity (-27.49%), as it is currently unprofitable.